Qritive, a digital pathology and AI company based in Singapore, has announced a strategic collaboration with Roche to advance cancer diagnostics by integrating its AI-powered solutions with Roche’s navify® Digital Pathology platform. This partnership aims to enhance the accuracy and efficiency of cancer diagnosis for pathologists, providing them with advanced tools that streamline the identification and grading of tumors across various cancers, including colon, prostate, breast, and gastric. The integration of Qritive’s technology into the Roche platform reflects a shared commitment to leveraging AI for faster and more precise pathology reporting.
The AI modules developed by Qritive are designed to analyze whole slide images and produce clinically validated assessments that significantly improve pathology reporting speed and reduce misdiagnosis risks. The integration enables pathologists to deliver faster and more accurate diagnostic results, ultimately shortening the time to treatment and improving patient outcomes. By addressing common challenges in the pathology field, such as resource constraints and increasing workloads, this collaboration provides scalable, AI-driven support to healthcare professionals.
This collaboration with Roche further solidifies Qritive’s role in the global cancer diagnostics landscape, bringing its innovative pathology solutions to a broader audience and reinforcing its commitment to improving health outcomes through AI. By providing enhanced diagnostic capabilities, the partnership aims to meet the rising demand for efficient, accessible healthcare solutions and strengthen the adoption of AI technology in pathology practices.
(Source: Qritive)